This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
All content for Condensed IP is the property of Randy Noranbrock and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
Inland Diamond Products v Cherry Optical (Fed. Cir., October 15, 2025) 2024-1106
Condensed IP
10 minutes
3 weeks ago
Inland Diamond Products v Cherry Optical (Fed. Cir., October 15, 2025) 2024-1106
This opinion from the United States Court of Appeals for the Federal Circuit, dated October 15, 2025, concerns the case of Inland Diamond Products Co. v. Cherry Optical Inc. The court addresses an appeal from the U.S. District Court for the Eastern District of Wisconsin, which had granted summary judgment that Inland’s asserted patent claims were invalid for obviousness based on the doctrine of issue preclusion following previous inter partes reviews (IPRs). The Federal Circuit determined tha...
Condensed IP
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
